Core Viewpoint - The private equity sector, particularly firms like Blackstone and Apollo, is experiencing a reduction in price targets but remains favored for long-term investment despite recent market challenges [1][4][6]. Group 1: Company Performance - Evercore has lowered price targets for Blackstone from 197 to 180 and for Apollo from 160 to 145, while maintaining an outperform rating for both [1]. - Blackstone is set to report earnings soon, which may influence market sentiment [1]. - Apollo's stock has shown a rebound of approximately 3.5% recently, while other firms like Aries and Blue Owl have also seen gains [11]. Group 2: Market Trends - The alternative investment space, including private equity and private credit, is gaining traction as more advisors allocate investor funds into these products [2][4]. - The financial sector has underperformed in October, with healthcare up 5% and financials down 2%, indicating a shift towards quality investments [5][6]. - There is a growing interest in private infrastructure investments due to funding shortages in government and municipalities, suggesting a new avenue for private equity firms [7][8]. Group 3: Competitive Landscape - The private equity market is becoming increasingly competitive, with a notable auction receiving 36 bids, highlighting the intense interest in this sector [9]. - The IPO market for traditional manufacturing companies, typically owned by private equity firms, has not yet opened, posing a challenge for these firms [10].

Hologic is set for acquisition by alternative asset management entities Blackstone and TPG for up to $18.3bn in enterprise value, as part of a definitive agreement. The transaction is valued at a potential $79 per share. Stockholders of Hologic are poised to receive $76 per share in cash, with the possibility of an additional $3 per share through a contingent value right (CVR), which will be distributed in two potential payments of up to $1.50 each. The non-tradable CVR will be issued to the shareholder ...

Core Viewpoint - Stepstone Group (NASDAQ:STEP) is positioned in a competitive market, with a new price target set by Morgan Stanley indicating potential growth in stock value [1][4]. Group 1: Stock Performance - STEP's current stock price is $63.15, reflecting a 3.64% increase from its previous value [2][4]. - The stock has shown significant volatility over the past year, with a high of $70.38 and a low of $40.07 [2][4]. - Today's trading range for STEP has been between $60.77 and $63.58 [2]. Group 2: Market Metrics - The market capitalization of STEP is approximately $7.82 billion, indicating its size and market presence [3]. - The trading volume for STEP is 231,874 shares, which highlights the stock's liquidity and investor interest [3]. Group 3: Analyst Insights - Michael Cyprys from Morgan Stanley has set a new price target of $66 for STEP, suggesting a potential increase of 5.35% from its current price [1][4].

Core Insights - TPG is a global alternative asset firm focusing on private equity, real estate, and public market investments, with a current stock price of $56.52 and a price target set by Morgan Stanley at $63, indicating a potential increase of approximately 11.47% [1][6] Company Overview - TPG has a market capitalization of approximately $21.03 billion, positioning it as a significant player in the financial sector [4] - The company's stock price has shown volatility, with a high of $72.98 and a low of $37.52 over the past year [3][6] Recent Developments - TPG, in collaboration with Blackstone, announced a significant acquisition of Hologic for up to $18.3 billion, which involves purchasing all outstanding shares at $76 each in cash [2][5] - This acquisition marks a strategic move into the healthcare sector, aligning with TPG's interest in diversifying and strengthening its investment portfolio [2][5] Market Activity - TPG's stock price currently stands at $56.58, reflecting a 1.35% increase or $0.76, with today's trading volume at 343,613 shares, indicating active investor interest [3][4]

Core Insights - KKR & Co. Inc. is a global investment firm managing various alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, and is known for strategic investments and partnerships that drive growth [1] - Morgan Stanley has set a price target of $166 for KKR, indicating a potential price increase of about 35.4% from its current stock price of $122.60, reflecting confidence in KKR's strategic moves [2][5] - KKR's recent investment in Peak Re, in collaboration with Quadrantis Capital, enhances Peak Re's financial backing and aligns with KKR's strategy of expanding influence in diverse sectors [3][5] - KKR's stock has shown significant volatility over the past year, with a high of $170.40 and a low of $86.15, and currently has a market capitalization of approximately $109.15 billion [4][5] - The stock has traded between $120.06 and $123.04 today, with an active trading volume of 1,217,389 shares [4]

Core Insights - Blackstone is a leading global investment firm specializing in private equity, real estate, credit, and hedge fund investment strategies, known for strategic acquisitions across various sectors [1] - Morgan Stanley maintains an "Overweight" rating for Blackstone, raising the price target from $200 to $215, indicating confidence in the stock's potential [2][6] - Blackstone's acquisition of Hologic for up to $18.3 billion emphasizes its strategic focus on the healthcare sector, aligning with its goal to expand in high-growth industries [3][6] Stock Performance - Blackstone's stock is currently trading at $161.67, reflecting a 0.77% increase, with a trading range today between $159.81 and $162.15 [4][6] - Over the past year, the stock has shown significant volatility, reaching a high of $200.96 and a low of $115.66, indicating potential for growth [4][6] Market Position - Blackstone's market capitalization is approximately $194 billion, with a trading volume of 522,544 shares, reflecting a strong position in the investment industry [5]

Core Viewpoint - Blackstone and TPG have agreed to acquire all outstanding shares of a women's health company for $76 per share in cash [1] Company Summary - The acquisition involves a cash payment of $76 for each share of the women's health company [1]

Blackstone and TPG agreed to acquire medical-device maker Hologic Inc. for as much as $18.3 billion, including debt, as private equity dealmaking accelerates in a bumper M&A market https://t.co/3cQXhne8wR ...

Core Viewpoint - Blackstone and TPG have reached an agreement to acquire Hologic, a medical diagnostics firm, in a deal valued at up to $18.3 billion [1] Company Summary - The acquisition involves two major investment firms, Blackstone and TPG, indicating strong interest in the medical diagnostics sector [1] - Hologic is positioned within the healthcare industry, specifically focusing on medical diagnostics, which is a critical area for investment given the ongoing demand for healthcare solutions [1] Financial Summary - The total deal value for the acquisition of Hologic is up to $18.3 billion, highlighting the significant financial commitment from Blackstone and TPG [1]

Today in Bloomberg Deals: Blackstone and TPG near a giant LBO of medical device maker Hologic. Also, EQT circles secondaries firms while Kering backs away from beauty. https://t.co/0ZYw3wR31m ...